Transgene SA has downplayed the significance of the Phase III failure of oncolytic virus Pexa-Vec, noting the differences between the out-licensed asset and the rest of its pipeline.
Transgene Downplays Impact Of Pexa-Vec Phase III Cancer Trial Failure
A late-phase assessment of the oncolytic virus in liver cancer patients was stopped early for futility but Transgene thinks the failure is an isolated event.
More from Clinical Trials
More from R&D
• By
Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.
• By
While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.
• By
AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.